Emyria Advances PTSD and Depression Treatments, Expands Clinic Capacity Amid Funding Talks

Sustained Clinical Success in PTSD Treatment

Emyria Limited (ASX: EMD) has delivered encouraging interim results from its unique PTSD treatment program, demonstrating durable and clinically significant improvements in patient outcomes. Analysis of eight patients three months post-treatment revealed a 62.5% rate of clinically significant symptom reduction, measured by a 10-point or greater decrease in PCL-5 scores, a standard PTSD symptom scale. Quality of life improvements were even more pronounced, with 75% of patients reporting significant gains according to ReQoL-10 assessments.

Notably, the average PTSD symptom score dropped by nearly 30 points, crossing below the diagnostic threshold for PTSD, while quality of life scores improved by 119%. The absence of patient drop-outs underscores the program’s tolerability and engagement, reinforcing Emyria’s trauma-informed care model as a promising intervention in mental health treatment.

Expanding Mental Health Offerings with New TRD Program

Building on its PTSD success, Emyria launched a therapy program targeting treatment-resistant depression (TRD) in February 2025. This initiative addresses a significant unmet need, as up to one-third of Australians with depression do not respond to conventional therapies. Early feedback from patients and clinicians has been positive, positioning Emyria to broaden its impact across critical mental health conditions.

Scaling Capacity with New Empax Centre

To meet rising demand, Emyria opened a second Empax Centre at Perth Clinic, a licensed mental health hospital, in April 2025. This facility increases treatment capacity by 50% and is designed to satisfy third-party funding requirements, facilitating broader patient access. Over 30 patients have now commenced or completed treatment across Empax Centres, with further expansion planned on Australia’s East Coast.

Advancing Funding Partnerships and Leadership

Emyria is actively engaging with private health insurers, workers’ compensation schemes, and government bodies, leveraging its growing real-world data to demonstrate treatment value. The company expects to launch funded pilot programs before the second half of 2025, which will be critical for establishing recurring revenue streams and scaling operations.

Leadership changes implemented earlier in the year have positioned Emyria for growth, with Greg Hutchinson appointed Executive Chairman to drive operational scale-up, and Dr. Michael Winlo assuming the role of Chief Scientific Officer to focus on clinical innovation and research development.

Financial Position and Drug Development Progress

Financially, Emyria reported a net operating cash outflow of $766,000 for the quarter, balanced by customer receipts of $359,000 and a $1 million equity raise from Executive Chairman Greg Hutchinson. The company ended the quarter with $1.78 million in cash, maintaining prudent capital management as it invests in clinical scale and funder engagement.

On the drug development front, Emyria continues its collaboration with the University of Western Australia to advance MDMA-inspired compounds MX-100 and MX-200 through preclinical stages, supported by non-dilutive grants. Additionally, the pharmaceutical cannabinoid Rx7 is progressing through NIH-backed preclinical screening for pain management, underscoring Emyria’s diversified pipeline in mental health and neurological conditions.

Looking Ahead

Emyria is poised to lead a transformation in mental health care by integrating clinical services, real-world data, and innovative drug development. The coming months will be pivotal, with the rollout of funded pilot programs, further Empax Centre expansions, and continued clinical validation expected to drive both patient impact and shareholder value.